A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas

Inclusion Criteria:

- Adult patients, >/= 18 years of age

- Patients with multiple basal cell carcinomas, including patients with Gorlin
syndrome, with at least 6 clinically evident basal cell carcinomas at the time of
randomization, at least 3 of which measure 5 mm or more in diameter (target lesions)

- Histopathologic confirmation that at least one of the three target lesions is basal
cell carcinoma

- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2

- Adequate renal and hepatic function and hematopoietic capacity

- Women of childbearing potential must agree to use contraception as defined by
protocol during treatment and for at least 7 months after completion of study
treatment

- Male patients with female partners of childbearing potential must agree to use
contraception as defined by protocol during treatment and for 2 months after
completion of study treatment

Exclusion Criteria:

- Inability or unwillingness to swallow capsules

- Pregnant or breastfeeding women

- Any metastatic basal cell carcinoma

- Locally advanced basal cell carcinoma lesion that is considered to be inoperable or
to have medical contraindications to surgery

- Recent (.i.e. within the past 28 days prior to randomization) or current
participation in another experimental drug study